Patrys Ltd
ASX:PAB
Intrinsic Value
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dil... [ Read More ]
The intrinsic value of one PAB stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.009 AUD, Patrys Ltd is Undervalued by 12%.
Valuation Backtest
Patrys Ltd
Run backtest to discover the historical profit from buying and selling PAB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Patrys Ltd
Current Assets | 5.2m |
Cash & Short-Term Investments | 4.5m |
Receivables | 654k |
Other Current Assets | 112.1k |
Non-Current Assets | 374.3k |
PP&E | 3k |
Intangibles | 371.3k |
Other Non-Current Assets | -10 |
Current Liabilities | 584.2k |
Accounts Payable | 284.1k |
Accrued Liabilities | 300.2k |
Earnings Waterfall
Patrys Ltd
Revenue
|
1.7m
AUD
|
Operating Expenses
|
-6.8m
AUD
|
Operating Income
|
-5.1m
AUD
|
Other Expenses
|
0
AUD
|
Net Income
|
-5.1m
AUD
|
Free Cash Flow Analysis
Patrys Ltd
PAB Profitability Score
Profitability Due Diligence
Patrys Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Patrys Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
PAB Solvency Score
Solvency Due Diligence
Patrys Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Patrys Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PAB Price Targets Summary
Patrys Ltd
Shareholder Return
PAB Price
Patrys Ltd
Average Annual Return | 11.27% |
Standard Deviation of Annual Returns | 42.72% |
Max Drawdown | -90% |
Market Capitalization | 18.5m AUD |
Shares Outstanding | 2 057 449 984 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
Contact
IPO
Employees
Officers
The intrinsic value of one PAB stock under the Base Case scenario is 0.01 AUD.
Compared to the current market price of 0.009 AUD, Patrys Ltd is Undervalued by 12%.